We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
In the latest trading session, Pfizer (PFE - Free Report) closed at $30.11, marking a +2.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the Dow gained 1.02%, and the Nasdaq, a tech-heavy index, lost 0.02%.
Coming into today, shares of the drugmaker had gained 6.13% in the past month. In that same time, the Medical sector gained 1.01%, while the S&P 500 gained 0.67%.
The upcoming earnings release of Pfizer will be of great interest to investors. The company's earnings report is expected on November 3, 2026. It is anticipated that the company will report an EPS of $0.72, marking a 17.24% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.13 billion, down 3.14% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.95 per share and revenue of $62.49 billion, indicating changes of -8.39% and -0.15%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.01% lower. Pfizer currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Pfizer is at present trading with a Forward P/E ratio of 9.99. This expresses a discount compared to the average Forward P/E of 16.86 of its industry.
It is also worth noting that PFE currently has a PEG ratio of 2. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 217, placing it within the bottom 12% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Pfizer (PFE - Free Report) closed at $30.11, marking a +2.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the Dow gained 1.02%, and the Nasdaq, a tech-heavy index, lost 0.02%.
Coming into today, shares of the drugmaker had gained 6.13% in the past month. In that same time, the Medical sector gained 1.01%, while the S&P 500 gained 0.67%.
The upcoming earnings release of Pfizer will be of great interest to investors. The company's earnings report is expected on November 3, 2026. It is anticipated that the company will report an EPS of $0.72, marking a 17.24% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $16.13 billion, down 3.14% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $2.95 per share and revenue of $62.49 billion, indicating changes of -8.39% and -0.15%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.01% lower. Pfizer currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Pfizer is at present trading with a Forward P/E ratio of 9.99. This expresses a discount compared to the average Forward P/E of 16.86 of its industry.
It is also worth noting that PFE currently has a PEG ratio of 2. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 217, placing it within the bottom 12% of over 250 industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow PFE in the coming trading sessions, be sure to utilize Zacks.com.